Primary mechanisms of action include: Enhanced insulin secretion : GLP-1 receptor agonists stimulate glucose-dependent insulin release from pancreatic beta cells, meaning insulin secretion increases when blood glucose is elevated but not when glucose levels are normal or low, reducing hypoglycemia risk Suppressed glucagon secretion : These medications inhibit glucagon release from pancreatic alpha cells, decreasing hepatic glucose production Delayed gastric emptying : GLP-1 receptor activation slows the rate at which food leaves the stomach, moderating postprandial glucose excursions Central appetite regulation : GLP-1 receptors in the brain, particularly in areas controlling satiety and food reward, are activated, leading to reduced appetite and caloric intake These combined effects result in improved glycemic control in patients with type 2 diabetes and significant weight loss in both diabetic and non-diabetic individuals

This is especially relevant during the early weeks of treatment when eating habits are changing, and appetite suppression tends to be most pronounced
We performed a literature search using Google Scholar and PubMed with the keywords migraine, IIH, bariatric surgery, gastric banding, gastric sleeve, gastric bypass, weight loss medications, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), lipase inhibitors, and sympathomimetic amines
We'll explore its specific uses and how it differs from dual-agonist therapies
My husband knew I didnt have a overeating problem- and Id conquered my binge eating/emotional eating problems from years back quite some time ago
Leptin has pro-inflammatory properties and upregulates the secretion of inflammatory cytokines (39)